文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens.

作者信息

Martin-Orozco Natalia, Wang Yi-Hong, Yagita Hideo, Dong Chen

机构信息

University of Texas M.D. Anderson Cancer Center, 7455 Fannin, Houston, TX 77030, USA.

出版信息

J Immunol. 2006 Dec 15;177(12):8291-5. doi: 10.4049/jimmunol.177.12.8291.


DOI:10.4049/jimmunol.177.12.8291
PMID:17142723
Abstract

Constitutive presentation of tissue Ags by dendritic cells results in tolerance of autoreactive CD8+ T cells; however, the underlying molecular mechanisms are not well understood. In this study we show that programmed death (PD)-1, an inhibitory receptor of the CD28 family, is required for tolerance induction of autoreactive CD8+ T cells. An antagonistic Ab against PD-1 provoked destructive autoimmune diabetes in RIP-mOVA mice expressing chicken OVA in the pancreatic islet cells, which received naive OVA-specific CD8+ OT-I cells. This effect was mediated by the PD ligand (PD-L) PD-L1 but not by PD-L2. An increased number of effector OT-I cells recovered from the pancreatic lymph nodes of anti-PD-L1-treated mice showed down-regulation of PD-1. Furthermore, the blockade of PD-1/PD-L1 interaction during the priming phase did not significantly affect OT-I cell division but enhanced its granzyme B, IFN-gamma, and IL-2 production. Thus, during the presentation of tissue Ags to CD8+ T cells, PD-1/PD-L1 interaction crucially controls the effector differentiation of autoreactive T cells to maintain self-tolerance.

摘要

相似文献

[1]
Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens.

J Immunol. 2006-12-15

[2]
PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues.

J Immunol. 2007-10-15

[3]
Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.

J Immunol. 2005-6-1

[4]
Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade.

J Immunol. 2009-2-15

[5]
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

Nat Immunol. 2009-11

[6]
Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes.

J Immunol. 2005-12-1

[7]
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.

J Immunol. 2011-6-22

[8]
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.

Blood. 2007-7-1

[9]
Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model.

J Immunol. 2008-4-1

[10]
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy.

Blood. 2007-7-1

引用本文的文献

[1]
Optimized network inference for immune diseased single cells.

Front Immunol. 2025-7-24

[2]
PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy.

J Immunother Cancer. 2025-5-7

[3]
A Non-Coding Oligonucleotide Recruits Cutaneous CD11b Cells that Inhibit Thelper Responses and Promote Tregs.

Adv Sci (Weinh). 2024-8

[4]
Transmembrane domain-driven PD-1 dimers mediate T cell inhibition.

Sci Immunol. 2024-3-8

[5]
Early allogeneic immune modulation after establishment of donor hematopoietic cell-induced mixed chimerism in a nonhuman primate kidney transplant model.

Front Immunol. 2024-1-22

[6]
Refined control of CRISPR-Cas9 gene editing in : the creation of recombinant strains for therapeutic applications.

Front Immunol. 2023

[7]
PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens.

Nature. 2023-7

[8]
Diverse Neutrophil Functions in Cancer and Promising Neutrophil-Based Cancer Therapies.

Int J Mol Sci. 2022-12-13

[9]
CXCR5CD8 T cells: Potential immunotherapy targets or drivers of immune-mediated adverse events?

Front Med (Lausanne). 2022-10-13

[10]
Current insight into the regulation of PD-L1 in cancer.

Exp Hematol Oncol. 2022-7-30

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索